Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652372 | 0.94 | BRD4 (0.40) | BRD4CREBBPCSNK1EPDE4BEP300 | |
| SCHEMBL1653014 | 0.91 | PDE4B (0.46) | BRD4CREBBPPDE4BEP300MERTK | |
| SCHEMBL3033400 | 0.90 | PDE4A (0.52) | BRD4CREBBPPDE4BEP300PDE4A | |
| SCHEMBL3033404 | 0.89 | PDE4B (0.56) | CSNK1EPDE4BTAAR1ALDH1A1L3MBTL1 | |
| SCHEMBL4708371 | 0.87 | PDE4B (0.54) | BRD4CREBBPPDE4BEP300SLC34A1 | |
| SCHEMBL4708697 | 0.86 | BRD4 (0.46) | BRD4CREBBPCSNK1EPDE4BEP300 | |
| SCHEMBL4708743 | 0.85 | PDE4B (0.49) | BRD4CREBBPPDE4BMERTKPDE4A | |
| SCHEMBL3032335 | 0.85 | PDE4A (0.48) | BRD4CREBBPPDE4BEP300MERTK | |
| SCHEMBL3039917 | 0.83 | PDE4B (0.45) | BRD4CREBBPPDE4BEP300MERTK | |
| SCHEMBL3037450 | 0.83 | BRD4 (0.45) | BRD4CREBBPPDE4BEP300MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | claimed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | claimed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | claimed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | claimed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | claimed |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | disclosed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | disclosed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | disclosed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | disclosed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | disclosed |
| EP-1575926-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058729-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | BRD4 281/4885CREBBP 1645/4885CSNK1E 1329/4885 |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | PDE3A, PDE4A, PDE3B | BRD4 387/4885CREBBP 1705/4885CSNK1E 1485/4885 |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | BRD4 281/4885CREBBP 1645/4885CSNK1E 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.